Suicidal Risks in Report of Reports of Long-Term Treatment Trials for Major Depressive Disorder
- PMID: 27655729
- PMCID: PMC5408966
- DOI: 10.1093/ijnp/pyw084
Suicidal Risks in Report of Reports of Long-Term Treatment Trials for Major Depressive Disorder
Comment in
-
Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II.Int J Neuropsychopharmacol. 2017 Mar 1;20(3):281-284. doi: 10.1093/ijnp/pyw092. Int J Neuropsychopharmacol. 2017. PMID: 28003313 Free PMC article. No abstract available.
Comment on
-
Suicidal Risks in Reports of Long-Term Treatment Trials for Major Depressive Disorder.Int J Neuropsychopharmacol. 2015 Sep 13;19(3):pyv107. doi: 10.1093/ijnp/pyv107. Int J Neuropsychopharmacol. 2015. PMID: 26371184 Free PMC article. Review. No abstract available.
References
-
- Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. (2010) Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 27:964–976. - PubMed
-
- US Food and Drug Administration (2006. a) US Food and Drug Administration clinical review: relationship between antidepressant drugs and suicidality in adults. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf Accessed September 9, 2016.
-
- US Food and Drug Administration (2006. b) Statistical evaluation of suicidality in adults treated with antidepressants. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf Accessed September 9, 2016.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
